Core Viewpoint - The recent issuance of the "Guidelines for the Project Establishment of Surgical and Treatment Auxiliary Medical Service Price Items (Trial)" by the National Medical Insurance Administration aligns with the company's surgical robot business, which has successfully obtained registration certificates for various orthopedic surgical robots [1] Group 1: Company Developments - The company has developed a comprehensive digital orthopedic solution covering pre-operative, intra-operative, and post-operative stages with its surgical robots [1] - The company has successfully registered products including hip joint surgical robots, knee joint surgical robots, and unicompartmental surgical robots [1] Group 2: Industry Trends - The new policy aims to standardize pricing for surgical robots and remote surgeries, indicating a growing recognition and support for advanced medical technologies in the healthcare sector [1] - The company is actively responding to the national "Belt and Road" initiative, steadily advancing its international business layout [1]

Core Viewpoint - China Zhongfu (01763.HK) anticipates a decline in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, primarily due to decreased earnings from its nuclear medical equipment division and tax-related expenses from a subsidiary [1] Financial Performance - Revenue is expected to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, reflecting a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million and RMB 322 million, indicating a year-on-year reduction of about 20% to 25% [1] Operational Status - The company's operations are currently normal, despite the anticipated revenue and profit declines [1] - The decrease in revenue for the fiscal year 2025 is mainly attributed to a downturn in the nuclear medical equipment segment [1] - The profit reduction is significantly influenced by tax payments and penalties from the subsidiary Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd. [1]

Group 1 - The stock price of Dongxing Medical (301290) has shown an upward trend, closing at 29.74 yuan on February 11, up approximately 3.23% from 28.81 yuan on February 5 [1] - On February 11, the stock increased by 1.78% with a trading volume of about 51.9 million yuan, although there was a net outflow of 177.20 million yuan from main funds, indicating short-term capital divergence [1] - As of February 12, the stock price slightly corrected to 29.41 yuan, down 1.11% for the day, but still up 2.08% over the past five days, outperforming the broader market [1] Group 2 - The number of shareholders in Dongxing Medical has increased, with a total of 9,302 shareholders as of January 30, reflecting a 3.44% increase, indicating heightened investor participation [2] - As of February 10, the number of shareholders continued to grow, increasing by approximately 160 accounts, or 1.72%, suggesting sustained market interest [2] - The company focuses on the anastomosis device industry chain and has not announced any other significant events recently [2]

Core Viewpoint - China Zhongfu (01763) anticipates a decline in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, primarily due to decreased earnings from its nuclear medical equipment division and tax-related expenses from a subsidiary [1] Financial Performance - Revenue is expected to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, reflecting a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million and RMB 322 million, indicating a year-on-year reduction of about 20% to 25% [1] Operational Status - The company's operations are currently running normally, despite the anticipated revenue and profit declines [1]

Group 1 - The core transaction involved Aibo Medical, with a total of 35,000 shares traded on February 12, resulting in a transaction amount of 2.415 million yuan, which accounted for 2.37% of the total trading volume for that day [1][2] - The transaction price was set at 69 yuan per share, representing a premium of 15.1% over the market closing price of 59.95 yuan [1][2]

Group 1 - The core point of the article is that Chunli Medical (688236.SH) is currently trading at 22.12 yuan, reflecting a decline of 3.24% and is in a state of breaking its initial public offering price [1] - Chunli Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 30, 2021, with an initial offering price of 29.81 yuan and issued a total of 38.428 million shares [1] - The total amount raised during the IPO was 1.145 billion yuan, with a net amount of 1.067 billion yuan after deducting issuance costs, which was 932.8717 million yuan less than the originally planned net fundraising amount [1] Group 2 - The company intended to raise 2 billion yuan for various projects, including orthopedic implants and supporting materials, R&D center construction, marketing network development, and working capital [1] - The total issuance costs amounted to 78.4104 million yuan, with Huatai United Securities receiving a sponsorship fee of 1.5 million yuan and underwriting fees of 65.2359 million yuan [1]

Core Viewpoint - Aidi Te's dental industrial park construction is progressing as planned and is expected to commence production in the second half of this year, which will significantly enhance the company's overall capacity [1] Group 1: Company Development - The company is implementing a phased release of capacity in the new park based on market demand and order forecasts to ensure a precise match between capacity release and order growth [1] - The company aims to ensure that the newly added capacity is efficiently utilized and orderly digested [1]

Core Insights - The company is focusing on new product launches, expansion into overseas markets, and obtaining medical device registrations for its subsidiaries [1] Product Development Progress - The second-generation bipolar product line is expected to receive regulatory approval by the end of 2025 and aims for full market promotion in 2026, which is anticipated to become a new growth driver [2] Business Progress - North American sales are expected to experience fluctuations due to tariff policies, but the company is advancing its shipping plans through its Thailand factory and plans to gradually expand to other overseas regions [3] Subsidiary Development - The company's controlling subsidiary received three Class II medical device registrations in December 2025, covering endoscopic equipment, with a validity period until December 2030, which will help enrich the product line, although the impact on future performance remains uncertain [4]

Company Performance - The company's stock price has shown a downward adjustment, with a decline of 3.95% over the past 7 days, and a single-day drop of 3.24% on February 12, closing at 22.12 yuan [1][2] - Despite significant growth in revenue and net profit, with a year-on-year increase of 213.21% in net profit attributable to the parent company, the positive performance has not alleviated short-term negative market sentiment [5] Industry Environment - The National Healthcare Security Administration reported typical cases of commercial bribery in the orthopedic field, revealing kickback ratios as high as 30%-40%, indicating a "golden sales" phenomenon in the industry [3] - Although leading companies, including the company in question, have generally forecasted revenue growth for 2025, there are concerns that regulatory actions may have a long-term impact on sales models and profitability within the industry [3] Market Sentiment - Despite a 16.56% increase in financing balance over the past 5 days, there was a net outflow of 337.38 thousand yuan in main funds on February 12, indicating a net selling state by large investors [4] - The stock has experienced a significant decline of 19.15% over the past 20 days, reflecting cautious market sentiment [4]

有投资者在互动平台向可孚医疗提问："董秘好，公司没有发布业绩预告，现在能否发布业绩快报，提 升投资者信心？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，可孚医疗回应称："尊敬的投资者，您好！公司严格按照相关法律法规及规范性文件的 规定履行信息披露义务，根据目前财务部门的初步测算，公司2025年度经营业绩未触及需披露业绩预告 或业绩快报的情形，因此无需披露相关业绩预告或业绩快报。公司2025年年度报告预约披露时间为2026 年3月10日，具体经营及财务数据请以届时公司在指定信息披露媒体披露的定期报告为准。感谢您的关 注。" ...